Guerbet SA (EPA:GBT)

France flag France · Delayed Price · Currency is EUR
19.70
-0.06 (-0.30%)
Apr 29, 2025, 12:52 PM CET
-47.33%
Market Cap 249.05M
Revenue (ttm) 851.12M
Net Income (ttm) 16.08M
Shares Out 12.60M
EPS (ttm) 1.28
PE Ratio 15.48
Forward PE 9.43
Dividend 0.50 (2.53%)
Ex-Dividend Date Jul 1, 2024
Volume 733
Average Volume 24,158
Open 19.80
Previous Close 19.76
Day's Range 19.70 - 19.84
52-Week Range 17.42 - 40.25
Beta 0.78
RSI 42.92
Earnings Date Sep 24, 2025

About Guerbet

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1926
Employees 2,905
Stock Exchange Euronext Paris
Ticker Symbol GBT
Full Company Profile

Financial Performance

In 2024, Guerbet's revenue was 851.12 million, an increase of 6.97% compared to the previous year's 795.65 million. Earnings were 16.08 million, a decrease of -32.61%.

Financial Statements

News

There is no news available yet.